As a new wave of interest in HIV therapeutic vaccines hits the biotech world, a team of Spanish researchers claims to have developed such a vaccine that temporarily halts growth of the HIV virus in patients.
HIV patients rely on a bevy of drugs to keep their illness under control, sticking to a strict regimen to maintain health. But let's face it: Adherence is a challenge and drug side effects can be rough. Enter HIV therapeutic vaccines. Read more >>
Norway's Bionor Pharma landed $1.7 million from the Research Council of Norway's Globvac program to learn more about what role a vaccine can play in eliminating HIV.
Bionor's latest HIV vaccine, Vacc-C5, is ready to go into therapeutic clinical trials at Oslo University Hospital.
The therapeutic HIV vaccine that the company nearly shelved in October 2011, Bionor's Vacc-4X, was safe given nasally to HIV-positive patients also on antiretrovirals.
Norwegian biotech Bionor Pharma has released results from a study of its therapeutic HIV vaccine, Vacc-4x. After initially planning to shelve the vaccine last October, the company is now plotting